RxDoctor Payments Data

Thomas Turnage, MD

Clinical Cardiac Electrophysiology · Mobile, ALNPI 1336464676

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $55,125 of the $70,878 with a category attached, or 77.8%. Medical Device Business Services, Inc. accounts for 61.0% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $18,507, 10.0 times the $1,857 reported in 2019.

$70,878in general payments, 2019–2025

Across 413 payments — averaging $171.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$43K
  • Biosense Webster, Inc.$16K
  • Boston Scientific$4K
  • Medtronic$3K
  • Abbott$958
  • Novartis$674
  • plus $3K from 25 others

What the payments were for

  • Consulting fees$55,12578%
  • Travel & lodging$5,2287%
  • Food & beverage$10,23014%
  • Education$2940%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$70,878 in reported general payments places this provider in the 85th percentile of 42 clinical cardiac electrophysiology providers in Alabama.

See all clinical cardiac electrophysiology providers in Alabama

Medicare billing

Part B allowed, 2024
$264,997
Medicare patients
553
Services billed
4,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban818$691,006
XareltoRivaroxaban242$200,622
EntrestoSacubitril/Valsartan106$103,684
JardianceEmpagliflozin24$25,307
Flecainide Acetate123$8,376
Metoprolol Succinate416$4,700
Amiodarone Hcl298$4,162
Carvedilol226$2,444
Sucralfate75$1,816
Amlodipine Besylate221$1,565
Atorvastatin Calcium118$1,528
Losartan Potassium77$1,142
Dofetilide16$1,040
ClopidogrelClopidogrel Bisulfate91$980
Diltiazem 24hr Er (Cd)Diltiazem Hcl26$868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$323$691,006818 claims
Johnson & JohnsonXarelto$633$200,622242 claims
NovartisEntresto$674$103,684106 claims
Boehringer IngelheimJardiance$41$25,30724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 42 clinical cardiac electrophysiology providers in Alabama.

Other clinical cardiac electrophysiology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →